Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts - 11/12/19
Abstract |
Background |
Despite the availability of different therapeutic modalities, treatment of recalcitrant common warts is still challenging. Cervarix (GlaxoSmithKline, Brentford, UK), a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts.
Objectives |
To evaluate the beneficial effects and tolerability of intramuscular versus intralesional bivalent HPV vaccine in the treatment of recalcitrant common warts.
Methods |
The study included 44 adult patients with multiple recalcitrant common warts; 22 patients received intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts, and the other 22 patients received intralesional injection of 0.1 to 0.3 mL of bivalent HPV vaccine into the largest wart at 2-week intervals until complete clearance or for a maximum of 6 sessions.
Results |
Complete clearance of warts was observed in 18 patients (81.8%) of the intralesional group and 14 patients (63.3%) of the intramuscular group; however, the difference was not statistically significant. Adverse effects were transient and insignificant, and no recurrence was reported in either group.
Limitations |
Small study sample and different dosing schedules.
Conclusions |
Bivalent HPV vaccine, particularly by intralesional injection, seems to be a potential therapeutic option for the treatment of multiple recalcitrant common warts.
Le texte complet de cet article est disponible en PDF.Key words : bivalent HPV vaccine, HPV vaccines, recalcitrant warts
Abbreviation used : IL
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 82 - N° 1
P. 94-100 - janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?